Highlights
KLSE: DPHARMA (7148)       DUOPHARMA BIOTECH BHD MAIN : Health Care
Last Price Today's Change   Day's Range   Trading Volume
2.84   +0.02 (0.71%)  2.81 - 2.85  419,400
Trade this stock with T+7 trading account. Find out more.

Financials


Market Cap: 2,006 Million

Market Cap 2,006 Million
NOSH 706 Million

Latest Audited Result:  31-Dec-2020

Latest Audited Result: 31-Dec-2020
Announcement Date 28-Apr-2021
Next Audited Result: 31-Dec-2021
Est. Ann. Date: 28-Apr-2022
Est. Ann. Due Date: 29-Jun-2022

Latest Quarter:  31-Mar-2021 [#1]

Latest Quarter: 31-Mar-2021 [#1]
Announcement Date 03-May-2021
Next Quarter: 30-Jun-2021
Est. Ann. Date: 13-Aug-2021
Est. Ann. Due Date: 29-Aug-2021
QoQ | YoY   8.78%  |    29.89%

Annual (Unaudited) ( EPS: 8.30, P/E: 34.23 )

Revenue | NP to SH 569,902  |  58,610
RPS | P/RPS 80.68 Cent  |  3.52
EPS | P/E | EY 8.30 Cent  |  34.23  |  2.92%
DPS | DY | Payout % 6.50 Cent  |  2.29%  |  78.30%
NAPS | P/NAPS 0.91  |  3.12
YoY   6.04%
NP Margin | ROE 10.28%  |  9.12%
F.Y. | Ann. Date 31-Dec-2020  |  22-Feb-2021

T4Q Result ( EPS: 8.87, P/E: 32.01 )

Revenue | NP to SH 577,643  |  62,663
RPS | P/RPS 81.78 Cent  |  3.47
EPS | P/E | EY 8.87 Cent  |  32.01  |  3.12%
DPS | DY | Payout % 6.48 Cent  |  2.28%  |  73.06%
NAPS | P/NAPS 0.90  |  3.16
QoQ | YoY   6.92%  |    15.26%
NP Margin | ROE 10.85%  |  9.86%
F.Y. | Ann. Date 31-Mar-2021  |  03-May-2021

Annualized Result ( EPS: 9.97, P/E: 28.47 )

Revenue | NP to SH 665,816  |  70,456
RPS | P/RPS 94.26 Cent  |  3.01
EPS | P/E | EY 9.97 Cent  |  28.47  |  3.51%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   20.21%  |    29.89%
NP Margin | ROE 10.58%  |  11.09%
F.Y. | Ann. Date 31-Mar-2021  |  03-May-2021




Show?  YoY % Horiz. %

Last 10 FY Result
AQR T4Q 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 CAGR
Revenue 665,816 577,643 569,902 576,462 498,722 467,987 312,940 270,680 176,961 162,405 135,310 138,132 17.04%
  YoY % 15.26% 1.36% -1.14% 15.59% 6.57% 49.55% 15.61% 52.96% 8.96% 20.02% -2.04% -
  Horiz. % 482.01% 418.18% 412.58% 417.33% 361.05% 338.80% 226.55% 195.96% 128.11% 117.57% 97.96% 100.00%
PBT 92,704 81,606 76,157 70,809 59,666 51,796 31,479 49,755 46,509 40,175 35,298 34,728 9.11%
  YoY % 13.60% 7.15% 7.55% 18.68% 15.19% 64.54% -36.73% 6.98% 15.77% 13.82% 1.64% -
  Horiz. % 266.94% 234.99% 219.30% 203.90% 171.81% 149.15% 90.64% 143.27% 133.92% 115.68% 101.64% 100.00%
Tax -22,248 -18,943 -17,547 -15,536 -12,025 -9,696 -4,653 0 0 -7,900 -9,284 -8,023 9.08%
  YoY % -17.45% -7.96% -12.94% -29.20% -24.02% -108.38% 0.00% 0.00% 0.00% 14.91% -15.72% -
  Horiz. % 277.30% 236.11% 218.71% 193.64% 149.88% 120.85% 58.00% -0.00% -0.00% 98.47% 115.72% 100.00%
NP 70,456 62,663 58,610 55,273 47,641 42,100 26,826 49,755 46,509 32,275 26,014 26,705 9.12%
  YoY % 12.44% 6.92% 6.04% 16.02% 13.16% 56.94% -46.08% 6.98% 44.10% 24.07% -2.59% -
  Horiz. % 263.83% 234.65% 219.47% 206.98% 178.40% 157.65% 100.45% 186.31% 174.16% 120.86% 97.41% 100.00%
NP to SH 70,456 62,663 58,610 55,273 47,641 42,492 27,115 38,775 35,271 32,275 26,014 26,705 9.12%
  YoY % 12.44% 6.92% 6.04% 16.02% 12.12% 56.71% -30.07% 9.93% 9.28% 24.07% -2.59% -
  Horiz. % 263.83% 234.65% 219.47% 206.98% 178.40% 159.12% 101.54% 145.20% 132.08% 120.86% 97.41% 100.00%
Tax Rate 24.00 % 23.21 % 23.04 % 21.94 % 20.15 % 18.72 % 14.78 % - % - % 19.66 % 26.30 % 23.10 % -0.03%
  YoY % 3.40% 0.74% 5.01% 8.88% 7.64% 26.66% 0.00% 0.00% 0.00% -25.25% 13.85% -
  Horiz. % 103.90% 100.48% 99.74% 94.98% 87.23% 81.04% 63.98% 0.00% 0.00% 85.11% 113.85% 100.00%
Total Cost 595,360 514,980 511,292 521,189 451,081 425,887 286,114 220,925 130,452 130,130 109,296 111,427 18.43%
  YoY % 15.61% 0.72% -1.90% 15.54% 5.92% 48.85% 29.51% 69.35% 0.25% 19.06% -1.91% -
  Horiz. % 534.30% 462.17% 458.86% 467.74% 404.82% 382.21% 256.77% 198.27% 117.07% 116.78% 98.09% 100.00%
Net Worth 635,424 635,424 642,484 525,364 483,173 479,809 454,703 270,177 192,942 181,850 169,354 163,783 16.38%
  YoY % 0.00% -1.10% 22.29% 8.73% 0.70% 5.52% 68.30% 40.03% 6.10% 7.38% 3.40% -
  Horiz. % 387.97% 387.97% 392.28% 320.77% 295.01% 292.95% 277.62% 164.96% 117.80% 111.03% 103.40% 100.00%
Dividend
AQR T4Q 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 CAGR
Div - 45,783 45,891 40,937 36,403 23,711 18,132 15,843 25,679 24,293 19,434 24,983 6.98%
  YoY % 0.00% -0.24% 12.10% 12.46% 53.53% 30.77% 14.44% -38.30% 5.71% 25.00% -22.21% -
  Horiz. % 0.00% 183.25% 183.69% 163.86% 145.71% 94.91% 72.58% 63.42% 102.78% 97.23% 77.79% 100.00%
Div Payout % - % 73.06 % 78.30 % 74.06 % 76.41 % 55.80 % 66.87 % 40.86 % 72.81 % 75.27 % 74.71 % 93.56 % -1.96%
  YoY % 0.00% -6.69% 5.73% -3.08% 36.94% -16.55% 63.66% -43.88% -3.27% 0.75% -20.15% -
  Horiz. % 0.00% 78.09% 83.69% 79.16% 81.67% 59.64% 71.47% 43.67% 77.82% 80.45% 79.85% 100.00%
Equity
AQR T4Q 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 CAGR
Net Worth 635,424 635,424 642,484 525,364 483,173 479,809 454,703 270,177 192,942 181,850 169,354 163,783 16.38%
  YoY % 0.00% -1.10% 22.29% 8.73% 0.70% 5.52% 68.30% 40.03% 6.10% 7.38% 3.40% -
  Horiz. % 387.97% 387.97% 392.28% 320.77% 295.01% 292.95% 277.62% 164.96% 117.80% 111.03% 103.40% 100.00%
NOSH 706,026 706,026 706,026 682,292 661,881 278,959 278,959 166,776 138,807 138,817 138,815 138,799 19.79%
  YoY % 0.00% 0.00% 3.48% 3.08% 137.27% 0.00% 67.27% 20.15% -0.01% 0.00% 0.01% -
  Horiz. % 508.67% 508.67% 508.67% 491.57% 476.86% 200.98% 200.98% 120.16% 100.01% 100.01% 100.01% 100.00%
Ratio Analysis
AQR T4Q 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 CAGR
NP Margin 10.58 % 10.85 % 10.28 % 9.59 % 9.55 % 9.00 % 8.57 % 18.38 % 26.28 % 19.87 % 19.23 % 19.33 % -6.77%
  YoY % -2.49% 5.54% 7.19% 0.42% 6.11% 5.02% -53.37% -30.06% 32.26% 3.33% -0.52% -
  Horiz. % 54.73% 56.13% 53.18% 49.61% 49.41% 46.56% 44.34% 95.09% 135.95% 102.79% 99.48% 100.00%
ROE 11.09 % 9.86 % 9.12 % 10.52 % 9.86 % 8.86 % 5.96 % 14.35 % 18.28 % 17.75 % 15.36 % 16.31 % -6.25%
  YoY % 12.47% 8.11% -13.31% 6.69% 11.29% 48.66% -58.47% -21.50% 2.99% 15.56% -5.82% -
  Horiz. % 68.00% 60.45% 55.92% 64.50% 60.45% 54.32% 36.54% 87.98% 112.08% 108.83% 94.18% 100.00%
Per Share
AQR T4Q 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 CAGR
RPS 94.30 81.82 80.72 84.49 75.35 167.76 112.18 162.30 127.49 116.99 97.47 99.52 -2.30%
  YoY % 15.25% 1.36% -4.46% 12.13% -55.08% 49.55% -30.88% 27.30% 8.98% 20.03% -2.06% -
  Horiz. % 94.75% 82.21% 81.11% 84.90% 75.71% 168.57% 112.72% 163.08% 128.10% 117.55% 97.94% 100.00%
EPS 9.96 8.88 8.46 8.25 7.26 15.09 9.62 19.17 25.41 23.25 18.74 19.24 -8.72%
  YoY % 12.16% 4.96% 2.55% 13.64% -51.89% 56.86% -49.82% -24.56% 9.29% 24.07% -2.60% -
  Horiz. % 51.77% 46.15% 43.97% 42.88% 37.73% 78.43% 50.00% 99.64% 132.07% 120.84% 97.40% 100.00%
DPS 0.00 6.48 6.50 6.00 5.50 8.50 6.50 9.50 18.50 17.50 14.00 18.00 -10.69%
  YoY % 0.00% -0.31% 8.33% 9.09% -35.29% 30.77% -31.58% -48.65% 5.71% 25.00% -22.22% -
  Horiz. % 0.00% 36.00% 36.11% 33.33% 30.56% 47.22% 36.11% 52.78% 102.78% 97.22% 77.78% 100.00%
NAPS 0.9000 0.9000 0.9100 0.7700 0.7300 1.7200 1.6300 1.6200 1.3900 1.3100 1.2200 1.1800 -2.84%
  YoY % 0.00% -1.10% 18.18% 5.48% -57.56% 5.52% 0.62% 16.55% 6.11% 7.38% 3.39% -
  Horiz. % 76.27% 76.27% 77.12% 65.25% 61.86% 145.76% 138.14% 137.29% 117.80% 111.02% 103.39% 100.00%
Adjusted Per Share Value based on latest NOSH - 706,330
AQR T4Q 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 CAGR
RPS 94.26 81.78 80.68 81.61 70.61 66.26 44.31 38.32 25.05 22.99 19.16 19.56 17.03%
  YoY % 15.26% 1.36% -1.14% 15.58% 6.57% 49.54% 15.63% 52.97% 8.96% 19.99% -2.04% -
  Horiz. % 481.90% 418.10% 412.47% 417.23% 360.99% 338.75% 226.53% 195.91% 128.07% 117.54% 97.96% 100.00%
EPS 9.97 8.87 8.30 7.83 6.74 6.02 3.84 5.49 4.99 4.57 3.68 3.78 9.12%
  YoY % 12.40% 6.87% 6.00% 16.17% 11.96% 56.77% -30.05% 10.02% 9.19% 24.18% -2.65% -
  Horiz. % 263.76% 234.66% 219.58% 207.14% 178.31% 159.26% 101.59% 145.24% 132.01% 120.90% 97.35% 100.00%
DPS 0.00 6.48 6.50 5.80 5.15 3.36 2.57 2.24 3.64 3.44 2.75 3.54 6.98%
  YoY % 0.00% -0.31% 12.07% 12.62% 53.27% 30.74% 14.73% -38.46% 5.81% 25.09% -22.32% -
  Horiz. % 0.00% 183.05% 183.62% 163.84% 145.48% 94.92% 72.60% 63.28% 102.82% 97.18% 77.68% 100.00%
NAPS 0.8996 0.8996 0.9096 0.7438 0.6841 0.6793 0.6438 0.3825 0.2732 0.2575 0.2398 0.2319 16.38%
  YoY % 0.00% -1.10% 22.29% 8.73% 0.71% 5.51% 68.31% 40.01% 6.10% 7.38% 3.41% -
  Horiz. % 387.93% 387.93% 392.24% 320.74% 295.00% 292.93% 277.62% 164.94% 117.81% 111.04% 103.41% 100.00%
Price Multiplier on Financial Quarter End Date
AQR T4Q 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 CAGR
Date AQR T4Q 31/12/20 31/12/19 31/12/18 29/12/17 30/12/16 31/12/15 31/12/14 31/12/13 31/12/12 30/12/11 -
Price 2.7500 2.7500 3.3800 1.4200 0.9500 2.5300 1.9800 2.6200 2.5000 2.5800 2.1300 2.0200 -
P/RPS 2.92 3.36 4.19 1.68 1.26 1.51 1.76 1.61 1.96 2.21 2.19 2.03 8.38%
  YoY % -13.10% -19.81% 149.40% 33.33% -16.56% -14.20% 9.32% -17.86% -11.31% 0.91% 7.88% -
  Horiz. % 143.84% 165.52% 206.40% 82.76% 62.07% 74.38% 86.70% 79.31% 96.55% 108.87% 107.88% 100.00%
P/EPS 27.56 30.98 40.72 17.53 13.20 16.61 20.37 11.27 9.84 11.10 11.37 10.50 16.24%
  YoY % -11.04% -23.92% 132.29% 32.80% -20.53% -18.46% 80.75% 14.53% -11.35% -2.37% 8.29% -
  Horiz. % 262.48% 295.05% 387.81% 166.95% 125.71% 158.19% 194.00% 107.33% 93.71% 105.71% 108.29% 100.00%
EY 3.63 3.23 2.46 5.70 7.58 6.02 4.91 8.87 10.16 9.01 8.80 9.52 -13.95%
  YoY % 12.38% 31.30% -56.84% -24.80% 25.91% 22.61% -44.64% -12.70% 12.76% 2.39% -7.56% -
  Horiz. % 38.13% 33.93% 25.84% 59.87% 79.62% 63.24% 51.58% 93.17% 106.72% 94.64% 92.44% 100.00%
DY 0.00 2.36 1.92 4.23 5.79 3.36 3.28 3.63 7.40 6.78 6.57 8.91 -15.67%
  YoY % 0.00% 22.92% -54.61% -26.94% 72.32% 2.44% -9.64% -50.95% 9.14% 3.20% -26.26% -
  Horiz. % 0.00% 26.49% 21.55% 47.47% 64.98% 37.71% 36.81% 40.74% 83.05% 76.09% 73.74% 100.00%
P/NAPS 3.06 3.06 3.71 1.84 1.30 1.47 1.21 1.62 1.80 1.97 1.75 1.71 8.98%
  YoY % 0.00% -17.52% 101.63% 41.54% -11.56% 21.49% -25.31% -10.00% -8.63% 12.57% 2.34% -
  Horiz. % 178.95% 178.95% 216.96% 107.60% 76.02% 85.96% 70.76% 94.74% 105.26% 115.20% 102.34% 100.00%
Price Multiplier on Announcement Date
AQR T4Q 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 CAGR
Date AQR T4Q - 13/02/20 18/02/19 28/02/18 24/02/17 23/02/16 24/02/15 26/02/14 25/02/13 22/02/12 -
Price 2.9300 2.9300 3.4200 1.6400 1.0300 2.9700 2.2300 2.6100 2.9200 2.6000 2.1700 2.1200 -
P/RPS 3.11 3.58 4.24 1.94 1.37 1.77 1.99 1.61 2.29 2.22 2.23 2.13 7.94%
  YoY % -13.13% -15.57% 118.56% 41.61% -22.60% -11.06% 23.60% -29.69% 3.15% -0.45% 4.69% -
  Horiz. % 146.01% 168.08% 199.06% 91.08% 64.32% 83.10% 93.43% 75.59% 107.51% 104.23% 104.69% 100.00%
P/EPS 29.36 33.01 41.20 20.24 14.31 19.50 22.94 11.23 11.49 11.18 11.58 11.02 15.76%
  YoY % -11.06% -19.88% 103.56% 41.44% -26.62% -15.00% 104.27% -2.26% 2.77% -3.45% 5.08% -
  Horiz. % 266.42% 299.55% 373.87% 183.67% 129.85% 176.95% 208.17% 101.91% 104.26% 101.45% 105.08% 100.00%
EY 3.41 3.03 2.43 4.94 6.99 5.13 4.36 8.91 8.70 8.94 8.64 9.08 -13.61%
  YoY % 12.54% 24.69% -50.81% -29.33% 36.26% 17.66% -51.07% 2.41% -2.68% 3.47% -4.85% -
  Horiz. % 37.56% 33.37% 26.76% 54.41% 76.98% 56.50% 48.02% 98.13% 95.81% 98.46% 95.15% 100.00%
DY 0.00 2.21 1.90 3.66 5.34 2.86 2.91 3.64 6.34 6.73 6.45 8.49 -15.31%
  YoY % 0.00% 16.32% -48.09% -31.46% 86.71% -1.72% -20.05% -42.59% -5.79% 4.34% -24.03% -
  Horiz. % 0.00% 26.03% 22.38% 43.11% 62.90% 33.69% 34.28% 42.87% 74.68% 79.27% 75.97% 100.00%
P/NAPS 3.26 3.26 3.76 2.13 1.41 1.73 1.37 1.61 2.10 1.98 1.78 1.80 8.52%
  YoY % 0.00% -13.30% 76.53% 51.06% -18.50% 26.28% -14.91% -23.33% 6.06% 11.24% -1.11% -
  Horiz. % 181.11% 181.11% 208.89% 118.33% 78.33% 96.11% 76.11% 89.44% 116.67% 110.00% 98.89% 100.00%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.


NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ Δ & YoY Δ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.


Analyze this stock with MQ Trader system
  12 people like this.
 
MZM2511 Report 2: Kanger International executive director Steven Kuah told reporters that, “the process of registering the Sinopharm vaccine (with NPRA) has started and we hope to receive some good news on its approval soon.”

(Source: https://www.freemalaysiatoday.com/category/nation/2021/05/27/sabah-signs-mou-with-private-firm-to-obtain-sinopharm-vaccine/ )

Report 6: The states are free to negotiate with drug makers Moderna and Sinopharm, whose vaccines have been approved by the World Health Organization . Khairy said that as long as the vaccines have been given the green light by the National Pharmaceutical Regulatory Agency, the states are free to procure them.

(Source: https://www.freemalaysiatoday.com/category/nation/2021/06/03/state-govts-free-to-purchase-moderna-sinopharm-vaccines/ )
17/07/2021 2:43 PM
MZM2511 Khairy also mentioned that Covid-19 vaccines will enter the private market by August. He said that private vaccination will help the government ramp up the national Covid-19 vaccination programme, as those who are able to pay for the vaccines will be able to do so.

“I also anticipate by about August, we will have a private vaccine market. So right now, it’s difficult for private because vaccines are in short supply. But by August, I think that there will be SOME COMPANIES who WILL BE APPROVED to bring in SOME PRIVATE VACCINES from China. I know Sinopharm and all that are going to be registered here,” Khairy added.

“That’s also part of the plan. I’ve been talking to the Ministry of Health to ensure that the private market by August can take off to help us.”

Source: https://codeblue.galencentre.org/2021/06/24/khairy-projects-40-population-fully-vaccinated-by-end-august/
17/07/2021 2:48 PM
MZM2511 On the Sputnik Covid-19 vaccine produced by Russia, Khairy said that Duopharma Biotech Bhd’s wholly-owned subsidiary, Duopharma (M) Sdn Bhd (DMSB), which holds the distribution rights to the product, has three months to register the vaccine with the National Pharmaceutical Regulatory Agency (NPRA), after inking an agreement with the government earlier this month.

He said that the NPRA still requires further information on the vaccine.

“However, NPRA also said that it would simplify the registration process if Sputnik gets emergency use (status) from the World Health Organisation (WHO). Sputnik has not received the EUL from WHO yet,” he said, referring to the Emergency Use Listing.

Source: https://www.malaymail.com/news/malaysia/2021/06/21/khairy-cansino-vaccine-to-arrive-in-malaysia-next-month-no-updates-yet-on-j/1983852
17/07/2021 2:56 PM
gohkimhock Nigeria has become the 68th country in the world to approve the Sputnik V. Total population of all countries where Sputnik V is approved for use now exceeds 3.7 billion people, which is nearly half of the global population.
17/07/2021 3:21 PM
rr1688 CHINESE BUSINESSMEN,STUDENTS etc very LOYAL to SINOPHARM ...when SINOPHARM open to private n goverment sectors...telephones ring non stop in private clinics...the sound of KA CHING...KA CHING...KA CHING...IT IS HAPPENNING IN SINGAPORE...
17/07/2021 3:46 PM
rr1688 TRAVELERS vaccinated with SINOPHARM less document required when visiting CHINA...i love to visit CHINA...
17/07/2021 4:02 PM
Bgt 9963 Good morning.!
18/07/2021 11:15 AM
Vaccineyes Good afternoon even
18/07/2021 1:28 PM
128Huat Let's go, DPHARMA!!
19/07/2021 8:41 AM
Bgt 9963 Good morning.!
19/07/2021 8:54 AM
HonLee Haha...Expected heading south...Any expert want to comment
19/07/2021 9:46 AM
mo1malaysia Actually what happen ah? People keep dumping leh... Really holland lo..
19/07/2021 11:45 AM
MZM2511 The Board of Directors of Kanger (“Company”) wishes to announce that Kanger Medical International Sdn. Bhd., a wholly-owned subsidiary of the Company had, on 19 July 2021 entered into Head of Agreement with Sparmak Medical Equipment Trading LLC for purchase of inactivated SARS-COV-2 Vaccines (Vero Cell) vaccine developed by Beijing Institute of Biological Products Co. Ltd., an affiliate of SINOPHARM CNBG.

Please refer to the full announcement as attached.

This announcement is dated 19 July 2021.

Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3176295

4.1 Quantity and specification of the Products

Quantity: Five Million (5,000,000) doses with an option to buy an additional Five Million (5,000,000) doses.
19/07/2021 2:07 PM
wayneforwin Heard that some internal people mentioning that KANGER previously build connection in Sabah and Sarawak and now they will working together with DUOPHARMA to distribute sinopharm to supply for Malaysia
19/07/2021 2:40 PM
Lifeunlimited https://www.klsescreener.com/v2/news/view/856153
19/07/2021 2:48 PM
Lifeunlimited https://www.nst.com.my/business/2021/07/709633/bursa-spotlight-duopharma-kanger-following-sinopharm-covid-19-vaccine
19/07/2021 2:59 PM
pearlcapital Kanger enters deal to buy five million doses of Sinopharm Covid-19 vaccines

https://www.theedgemarkets.com/article/kanger-enters-deal-buy-five-million-doses-sinopharm-covid19-vaccines
19/07/2021 3:25 PM
Kicimeow Ok tidur terus
19/07/2021 3:51 PM
mo1malaysia This counter like erectile dysfunction. Give viagra also cannot naik.
19/07/2021 4:07 PM
Valgrovest Patience lah...when it wake up it will fly up all the way !
19/07/2021 4:47 PM
Trevor777 Is Dparma being used as "second fiddle" again after playing the Sputnik V prop up man? Sputnik V had been dragged for miles and NPRA approval depends on WHO, whom are..hhmmm..

Dpharma, is said to be Registered Holder of Sinopharm, but Kanger has placed an order for 5 million doses ahead of Dpharma? Sinopharm is imported prepacked, and no FnF is necessary?

Secondly, Sinopharm is to be distributed to Private sectors and not used in NIP as with Pfizer and AZ?

Anyone with better understanding, please share..
21/07/2021 8:05 AM
Bgt 9963 Good morning.!
21/07/2021 8:37 AM
Newbie1198 Will it bounce back?
21/07/2021 4:28 PM
mo1malaysia Wont, give viagra also wont bounce back.. Mati pucuk punya counter. Disappointing...
21/07/2021 4:35 PM
Ron90 sure got govt contract, at leasi 2 million jabs.
21/07/2021 4:48 PM
Newbie1198 https://www.theedgemarkets.com/article/sinopharms-covid19-shot-induces-weaker-antibody-responses-delta-variant-%E2%80%94-study
21/07/2021 5:25 PM
rr1688 THAI stop exporting AZ...SINOPHARM the largest biotech in CHINA can take over...
21/07/2021 10:46 PM
gohkimhock Chile becomes the 69th country to register Sputnik V vaccine
22/07/2021 1:42 AM
mo1malaysia Mati la this counter. Really menyusahkan people...
22/07/2021 9:54 AM
startrader Back to gkove counters
22/07/2021 10:38 AM
Ron90 useless company, vaccine got approval pun cannot make money.. look at pharma, can produce 14 million doses faster supply 4 months in advance and also can sell to other countries.
22/07/2021 12:20 PM
juju Taking time to spike that will be stable
23/07/2021 7:50 AM
Bgt 9963 Good morning.!
23/07/2021 8:56 AM
433tikitaka all cb director should resign. very malas. tidur 24 hours
23/07/2021 4:49 PM
433tikitaka since before i knew this company run by malas people
23/07/2021 4:50 PM
433tikitaka so cannot go anywhere
23/07/2021 4:50 PM
433tikitaka luckily i cabut earlier at. invest in gloves and a bit in pharmaniaga
23/07/2021 4:51 PM
23/07/2021 4:51 PM
kermit21 https://www.orientaldaily.com.my/news/nation/2021/07/24/426400?fbclid=IwAR3OKhM44QTjk4R5qExXHvEQ8sCGhUpYUBZnOTVffR8EiwHcg1VBELH8dm0
24/07/2021 10:02 PM
rr1688 according to latest health expert report...booster shots are required every 6 months...biotech is worth usd750 billion...will be worth usd 1 TRILLION or more...astronomical...
25/07/2021 8:15 PM
rr1688 SPUTNIK V is expected to receive world of good news in the near future...awesome...
25/07/2021 8:38 PM
433tikitaka @rr1688 what you mean biotech worth 1trillion? this lousy company run by malas people. so nowhere
26/07/2021 3:30 PM
mo1malaysia This counter really champion.. Champion for Hari Hari Turun and Hari Hari Merah...
27/07/2021 9:24 AM
almond Ya. Haizz. Rrs cut loss cut profit. Push up 3.6 tat day, drop like rocket after 1hr. Funny. Really big shark toy
27/07/2021 9:43 AM
Valgrovest https://www.theedgemarkets.com/article/antibodies-sinovacs-covid19-shot-fade-after-about-six-months-booster-helps-%E2%80%94-study

Now they confirmed vaccine cannot last forever - the most 6 to 12 months. Demand for vaccine to last forever - buy vaccine counter for long term.
27/07/2021 10:09 AM
rr1688 SOUTH KOREA granted emergency use authorization to SPUTNIK V...logs fastest GDP GROWTH in decade at 5.9% for Q2...awesome...SPUTNIK V...
27/07/2021 7:05 PM
Trevor777 It's totally unbelievable at this moment and point in time of NIP roll-out that people still harbor the wishful thinking of Sputnik V landing in Malaysia, albeit missing the most crucial impacting moment.

Now with the Sinopharm Registered Holdership in hand, pray tell, what and when did you see or read any PROGRESS??????? It's all wayang, my friends, and you are all the SUCKERS!!!
28/07/2021 9:00 AM
rr1688 WHO regional director for europe HANS KLUGE said 'there are definitely grounds for optomism on the prospect of SPUTNIK V's approval by WHO' ...HUNGARY EU MEMMBER granted emergency use authorization for SPUTNIK V...awesome...SPUTNIK V...
28/07/2021 10:57 AM
rr1688 according to latest health expert report...booster shots are required every 6 months...biotech is worth usd 750 billion...will be worth usd 1 TRILLION...astronomical...
28/07/2021 2:45 PM
rr1688 YOU CAN DO IT...even you failed 97 years...HIDILYN DIAZ...GOLD is coming...
28/07/2021 2:55 PM